3 results
See protocol page 23This study is designed to assess the usability and functionality of the Reveal LINQ system. Data from the first 30 patients, with 30 days of follow-up, will be used to assess sensing performance and wireless capabilities of the…
The aim of the study is twofold. The first is the impact of DRL-21994 and the registered product on the release of vessels studied and compared. The second is the speed with which DRL-21994 is included in the body examined, as well as the degree of…
Primary Objectives:• Evaluate the safety and tolerability of sparsentan oral suspension (Population 1 and Population 2) and tablets (Population 3)• Assess changes in proteinuria after once-daily dosing of sparsentan oral suspension and tablets over…